Literature DB >> 19654986

Infliximab for the treatment of paediatric Crohn's disease: Obstacles to accessing a necessary therapy.

Anthony Otley1, Jeff Critch, J Decker Butzner.   

Abstract

Entities:  

Year:  2004        PMID： 19654986      PMCID： PMC2720467          DOI： 10.1093/pch/9.2.87

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


× No keyword cloud information.
  25 in total

Review 1.  The state of the art in the management of inflammatory bowel disease.

Authors:  Stephen B Hanauer; Daniel H Present
Journal:  Rev Gastroenterol Disord       Date:  2003

Review 2.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Authors:  William J Sandborn; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

Review 3.  Review article: safety of infliximab in clinical trials.

Authors:  S B Hanauer
Journal:  Aliment Pharmacol Ther       Date:  1999-09       Impact factor: 8.171

4.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

Authors:  S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts
Journal:  N Engl J Med       Date:  1997-10-09       Impact factor: 91.245

5.  Who best assesses Crohn's disease?

Authors:  H Holloway; W Mullen; J F Fielding
Journal:  Ir J Med Sci       Date:  1996 Apr-Jun       Impact factor: 1.568

6.  Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life.

Authors:  A Ferguson; D M Sedgwick; J Drummond
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

7.  Use of infliximab in pediatric patients with inflammatory bowel disease.

Authors:  M S Serrano; E Schmidt-Sommerfeld; T J Kilbaugh; R F Brown; J N Udall; E E Mannick
Journal:  Ann Pharmacother       Date:  2001 Jul-Aug       Impact factor: 3.154

Review 8.  Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada.

Authors:  R Panaccione
Journal:  Can J Gastroenterol       Date:  2001-06       Impact factor: 3.522

9.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

10.  Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.

Authors:  Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; David F Hendricks; Gregory F Keenan; Harland S Winter
Journal:  Am J Gastroenterol       Date:  2003-04       Impact factor: 10.864
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.